When does Imbruvica’s patent protection expire?
Imbruvica (ibrutinib) is protected by multiple patents and related “exclusivity” periods that can run on different timelines depending on the specific country, formulation, and patent family. That means there is no single universal “expiration date” for all of its legal protections.
To pin down the relevant dates for a specific jurisdiction, it’s important to look at each patent covering Imbruvica and how they line up against generic/biosimilar entry risk. DrugPatentWatch tracks these patent estates and provides an at-a-glance view of when each protection is expected to end. [1]
How do you figure out the exact expiry date for a specific Imbruvica patent?
Patent expiration for Imbruvica depends on what you mean by “expiry”:
- The end of a particular patent term (which varies by filing date and jurisdiction).
- The end of regulatory exclusivities (if applicable in that country).
- Whether the patent estate includes “secondary” patents (for new uses, formulations, dosing, or manufacturing changes) that can extend time before generic competitors can launch.
DrugPatentWatch is one of the easiest places to cross-check which patents drive the latest possible dates for generic entry. [1]
Can generics launch as soon as one patent expires?
Not usually. Even if one patent ends, other patents in the same estate can still block a generic product from launching in that market. Generic companies typically need a clear “freedom to operate” position across the remaining relevant patents, not just one.
That is why timelines often reflect the latest-expiring patent in the estate that is still enforceable for the product being pursued. [1]
Which Imbruvica protections are most likely to control launch timing?
The patents that typically matter most for launch timing are the ones with the latest expiration in the relevant country and those that cover the core product claims (not just narrow amendments). Secondary patents can also matter if they remain enforceable and are tied to claims that a generic would need to avoid or design around.
DrugPatentWatch’s patent-by-patent tracking is designed for identifying which specific patents are likely to control the risk window. [1]
Where can I check the latest Imbruvica expiry dates by country?
A practical way to get the exact dates (and see which patents are still active) is to use the DrugPatentWatch listing for Imbruvica. [1]
Sources:
[1] https://www.drugpatentwatch.com/